期刊文献+

滋阴降火散结中药辅助治疗Graves病的疗效及对血清干扰素诱导蛋白-10的影响 被引量:4

Effect of Nourishing-Yin Removing-Fire and Dissipating-Stagnation Decoction in Combination with Western Medicine Treatment on Thyroid Volumes and Interferon Induced Protein-10(IP-10)Levels in Patients with Graves Disease
下载PDF
导出
摘要 目的:探讨滋阴降火散结方辅助治疗Graves病(以下简称GD)的疗效及作用机制。方法:将100例初诊GD患者随机分为联合中药治疗组(A组)与常规治疗组(B组)各50例,两组均口服他巴唑15-30 mg/d,联合治疗组在此基础上加服滋阴降火散结方50 mL,3次/d。两组均连续用药12周。观察两组治疗前后甲状腺体积、甲状腺上动脉血流速度、甲状腺血管指数及血清IP-10的水平变化,同时与正常人群做比较,并行相关分析。结果:治疗后联合中药治疗组较常规治疗组更明显的降低甲状腺体积(P〈0.05)、甲状腺上动脉血流速度(P〈0.05)、甲状腺血管指数(P〈0.05)。新发GD患者血清IP-10的水平有意义增加同时伴有甲状腺血流增加,血清IP-10的水平与甲状腺上动脉最大收缩速度(STA-PSV)、甲状腺内血管生成指数(TVI)和甲状腺容量相关(r=0.67,0.73,0.70,P〈0.05)。联合中药治疗组较常规治疗组更明显的降低血清IP-10的水平(P〈0.05)。结论:滋阴降火散结方对活动期的GD伴甲状腺肿大疗效确切,能有效抑制甲状腺内血管形成,其机制可能为降低血清中IP-10水平。 Objective : To study the effect of the Nourishing-Yin Removing-Fire and Dissipating- Stagnation Decoction in combination with medicine treatment on thyroid volumes and serum interferon induced protein-10 ( IP-10 ) levels in patients with Graves disease ( GD ). Methods : 100 patients were divided into two groups : Group A was treated with methimazole ( MT ) combined with Nourishing-Yin Removing-Fire and Dissipating-Stagnation Decoction and Group B was treated with MT alone. Thyroid volumes, superior thyroid artery peak systolic velocity ( STA-PSV ), thyroid vascularity index ( TVI ) and serum IP-10 levels in patients were also observed in Group A and B before and after treatment. The correlation between thyroid volumes, STA-PSV, TVI and serum IP-10 levels in patients was analyzed. Results : The levels of serum IP-10 was increased significantly with increased intrathyroidal blood flow in newly diagnosed GD patients. There was a positive correlation between thyroid volumes, STA-PSV, TVI and serum IP-10 levels in patients ( r=0.67,0.73,0.70, P〈0.05 ). Thyroid volumes, superior thyroid artery peak systolic velocity ( STA-PSV ), thyroid vascularity index ( TVI ) and serum VEGF levels were decreased more in Group A than in Group B after treatment ( 23.88 ± 9.46 vs 31.70 ± 18.90; 67.37 ± 38.85 vs 85.60 ± 43.80; 0.203 ± 0.108 vs 0.250± 0.075; 80.1± 33.9 vs 107.6 ±44.8, P〈0.05 ). Conclusions : Nourishing- Yin Removing-Fire and Dissipating-Stagnation Decoction in combination with western medicine treatment can improve goiters more effectively than only traditional western medicine by decreasing serum IP-10 levels Of patients with GD.
出处 《辽宁中医药大学学报》 CAS 2015年第6期23-26,共4页 Journal of Liaoning University of Traditional Chinese Medicine
基金 辽宁省医学高峰建设工程项目(2010056)
关键词 GRAVES病 甲状腺体积 甲状腺内血管生成 干扰素诱导蛋白-10 滋阴降火散结方 Graves disease thyroid volumes intrathyroid vascularity interferon induced protein-10 ( IP-10 ) Chinese herbal medicine
  • 相关文献

参考文献11

  • 1中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:823
  • 2中华人民共和国卫生部.中药临床研究指导原则[M].北京:中国医药科技出版社,2002:226-230.
  • 3姜玉新,张淑琴,张缙熙,周新建,刘世贞.B超测量甲状腺体积(重量)与核素显像对比研究[J].中国超声医学杂志,1997,13(4):12-14. 被引量:19
  • 4Iitaka M, Miura S, Yamanaka K, et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis[J] .J Clin Endocrinol Metab, 1998,83 (11):3908-3912.
  • 5Antonelli A, Fallahi P, Rotondi M, et al. Increased serum CXCL10 in Graves'disease or autoimmune thyroiditis is not associated with hyper-or hypothyroidism perse, but is specifically sustained by the autoimmune, inflammatory process[J] .Eur J En-docrinol, 2006,154 (5):651.
  • 6Antonelli A, Rotondi M, Fallahi P. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves'disease or with toxic nodular goiter[J] .Clin Endocrinol Metab,2007,92 (4):1485.
  • 7Domberg J, Liu C, Papewalis C, et al. Circulating chemokines in patients with autoimmune thyroid diseases[J] .Horm Metab Res, 2008,40 (6):416.
  • 8Shih SR1, Chang JS, Lin LC, et al. The relationship between thyrotropin receptor antibody levels and intrathyroid vaseularity in patients with Graves' disease[J] .Exp Clin Endocrinol Diabetes, 2013,121 (1):1-5.
  • 9Corona G, Biagini C, Rotondi M, et al. Correlation between, clinical, biochemical, color Doppler ultrasound thyroid parameters, and CXCL-10 in autoimmune thyroid diseases[J] . Endocr J, 2008,55 (2):345.
  • 10Crescioli C, Cosmi L, Borgogni E, et al. Methimazole inhibits CXC ehemokine ligand 10 secretion in human thyrocytes[J] . Endocrinol,2007,195 (1):145.

二级参考文献14

  • 1白耀.甲状腺病学-基础与临床[M].北京:科学技术文献出版社,2004.388.
  • 2Davies TF, Larsen PR. Thyrotixicosis// Larsen PR, Kronenberg HM, Melmed S. Wlilliams textbook of endocrinology. 10th ed. Philadelphia: Saunders, 2002: 374-424.
  • 3Chiovato L, Babesino G, Pinchera A. Graves disease//DeGroot LJ, Jameson JL. Endocrinology. 4th ed. Philadelphia: Saunders, 2001 : 1422-1449.
  • 4Greenspan FS. The thyroid gland//Greenspan FS, Gardner DG. Basic and clinical endocrinology. New York: Lange /McGraw- Hill, 2001: 201-272.
  • 5Fisher DA. Disorders of the thyroid in the newborn and infant// Sperling MA. Pediatric endocrinology. 2nd ed. Philadelphia: Sannders, 2002 : 161-186.
  • 6Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med, 2000, 160:1573-1575.
  • 7American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract, 2002,8:457-469.
  • 8Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China. N Engl J Med, 2006, 354:2783-2793.
  • 9Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid, 2003,13 : 3-126.
  • 10Cooper DS. Antithyroid drugs. N Engl J Med, 2005, 352:905- 917.

共引文献840

同被引文献81

引证文献4

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部